NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
MAVYRET (glecaprevir and pibrentasvir) by AbbVie is p-glycoprotein inhibitors [moa]. Approved for hepatitis c. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAVYRET is an oral tablet combining glecaprevir and pibrentasvir, approved by the FDA on August 3, 2017, for the treatment of hepatitis C virus (HCV) infection. The product works through dual mechanisms: glecaprevir inhibits HCV NS3/4A protease while pibrentasvir targets the NS5A protein, both critical viral replication enzymes. MAVYRET represents a pangenotypic direct-acting antiviral (DAA) regimen offering simplified, short-duration treatment for HCV patients across all genotypes.
$0.2BPart D
10.6 years to LOEMechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Indications (1)
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Why This Matters for Your Career
Worked on MAVYRET at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.